{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T13:33:55Z","timestamp":1774186435220,"version":"3.50.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Improvements in coronary drug-eluting stent technology has focused on reducing the long-term complications associated with the effects of the residual footprint on the vessel wall. Although many of the newer stents have exhibited noninferiority to the durable polymer everolimus-eluting stent (DP-EES), they have yet to exhibit clear superiority. We compared the performance of the latest ultrathin strut biodegradable polymer sirolimus-eluting stents (BP-SES) to DP-EES.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We searched the electronic databases for randomized controlled trials comparing BP-SES to DP-EES. A random effect meta-analysis was performed using the Poisson regression model. The primary end point was target lesion failure (TLF), a composite of target vessel myocardial infarction (TVMI), cardiac death and target lesion revascularization (TLR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>There was no difference between the stents in stent thrombosis [incidence rate ratio (IRR)\u2009=\u20090.79, 95% confidence interval (CI) 0.58\u20131.06), TLR (IRR\u2009=\u20090.88, 95% CI 0.57\u20131.38), TVMI (IRR\u2009=\u20090.79, 95% CI 0.61\u20131.01), cardiac death (IRR\u2009=\u20090.99, 95% CI 0.76\u20131.29) and target vessel failure (IRR\u2009=\u20090.82, 95% CI 0.64\u20131.06). In addition, there was no difference in TLF (IRR\u2009=\u20090.82, 95% CI 0.64\u20131.06). There was evidence of reduced TLF in small vessels with BP-SES based on definition used (defined as \u22642.75\u2009mm; IRR 0.64, 95% CI 0.46\u20130.91 versus \u22643\u2009mm; IRR 1.11, 95% CI 0.90\u20131.36).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In our study, the performance of the latest generation BP-SES was comparable to DP-EES but failed to show superiority. The possible benefit in patients with small vessels should be explored future trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000000949","type":"journal-article","created":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T14:02:48Z","timestamp":1599400968000},"page":"459-465","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Ultrathin biodegradable polymer sirolimus-eluting stent versus contemporary durable polymer everolimus-eluting stent for percutaneous coronary intervention: a meta-analysis of randomized trials"],"prefix":"10.1097","volume":"32","author":[{"given":"Ankur","family":"Sethi","sequence":"first","affiliation":[{"name":"Robert Wood Johnson University Hospital and Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vamsi","family":"Kodumuri","sequence":"additional","affiliation":[{"name":"All Saints Hospital, Ascension Health System, Racine, Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinoy","family":"Prasad","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Loma Linda University, Loma Linda, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kassotis","sequence":"additional","affiliation":[{"name":"Robert Wood Johnson University Hospital and Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1056\/NEJMoa1607991","article-title":"Drug-eluting or bare-metal stents for coronary artery disease.","volume":"375","author":"B\u00f8naa","year":"2016","journal-title":"N Engl J Med"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(19)30474-X","article-title":"Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials.","volume":"393","author":"Piccolo","year":"2019","journal-title":"Lancet"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization.","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jacc.2019.11.058","article-title":"Stent-related adverse events >1 year after percutaneous\u2009coronary\u2009intervention.","volume":"75","author":"Madhavan","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","article-title":"Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings.","volume":"123","author":"Kolandaivelu","year":"2011","journal-title":"Circulation"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","article-title":"Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.","volume":"48","author":"Joner","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.carrev.2019.12.039","article-title":"The Orsiro ultrathin, bioresorbable-polymer sirolimus-eluting stent: a review of current evidence.","volume":"21","author":"Forrestal","year":"2020","journal-title":"Cardiovasc Revasc Med"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1161\/CIRCULATIONAHA.112.097014","article-title":"Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.","volume":"125","author":"Bangalore","year":"2012","journal-title":"Circulation"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.jacc.2017.10.010","article-title":"3-year clinical outcomes with\u2009everolimus-eluting bioresorbable\u2009coronary scaffolds: the\u2009ABSORB III trial.","volume":"70","author":"Kereiakes","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"264, W64","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"R11-20250729","first-page":"89","article-title":"A nonparametric \u2018Trim and Fill\u2019 method of accounting for publication bias in meta-analysis.","volume":"95","author":"Duval","year":"2000","journal-title":"J Am Stat Assoc"},{"key":"R13-20250729","first-page":"40","article-title":"Meta: an R package for meta-analysis.","volume":"7","author":"Schwarzer","year":"2007","journal-title":"R News"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jcin.2018.04.014","article-title":"Comparison of a novel biodegradable polymer sirolimus-eluting stent with\u2009a\u2009durable polymer everolimus-eluting stent: 5-year outcomes of the randomized BIOFLOW-II trial.","volume":"11","author":"Lef\u00e8vre","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.jcin.2020.02.019","article-title":"Ultrathin bioresorbable polymer sirolimus-eluting stents versus thin durable polymer everolimus-eluting stents: three-year outcomes from the randomized BIOFLOW V trial.","volume":"13","author":"Kandzari","year":"2020","journal-title":"J Am Coll Cardiol Intv"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(18)31715-X","article-title":"Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.","volume":"392","author":"Pilgrim","year":"2018","journal-title":"Lancet"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"649.e9","DOI":"10.1016\/j.clinthera.2020.02.014","article-title":"Comparison of the ultrathin strut, biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent in a Chinese population: the randomized BIOFLOW VI trial.","volume":"42","author":"Li","year":"2020","journal-title":"Clin Ther"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0140-6736(19)31877-X","article-title":"Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.","volume":"394","author":"Iglesias","year":"2019","journal-title":"Lancet"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.4244\/EIJ-D-18-01214","article-title":"BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months.","volume":"15","author":"Saito","year":"2019","journal-title":"Eurointervention"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcin.2016.10.017","article-title":"Randomized multicenter trial investigating\u2009angiographic outcomes of\u2009hybrid sirolimus-eluting stents with\u2009biodegradable polymer compared with\u2009everolimus-eluting stents with durable\u2009polymer in chronic total occlusions: the PRISON IV trial.","volume":"10","author":"Teeuwen","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2013.08.725","article-title":"Stent thrombosis with drug-eluting stents: is the paradigm shifting?.","volume":"62","author":"Palmerini","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jacc.2013.09.061","article-title":"Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.","volume":"63","author":"Palmerini","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.carrev.2017.11.009","article-title":"A comparison of the ultrathin Orsiro hybrid sirolimus-eluting stent with contemporary drug-eluting stents: a meta-analysis of randomized controlled trials.","volume":"19","author":"Lipinski","year":"2018","journal-title":"Cardiovasc Revasc Med"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12872-018-0902-5","article-title":"Safety and efficacy of ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer drug-eluting stents: a meta-analysis of randomized trials.","volume":"18","author":"Zhu","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijcard.2013.12.021","article-title":"Detailed comparison of intra-stent conditions 12 months after implantation of everolimus-eluting stents in patients with ST-segment elevation myocardial infarction or stable angina pectoris.","volume":"171","author":"Mizoguchi","year":"2014","journal-title":"Int J Cardiol"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"e1343","DOI":"10.4244\/EIJY15M12_09","article-title":"Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction.","volume":"12","author":"Pilgrim","year":"2016","journal-title":"Eurointervention"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jamacardio.2019.1776","article-title":"Outcomes in patients treated with thin-strut, very thin-strut, or ultrathin-strut drug-eluting stents in small coronary vessels: a prespecified analysis of the randomized BIO-RESORT trial.","volume":"4","author":"Buiten","year":"2019","journal-title":"JAMA Cardiol"},{"key":"R29-20250729","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.jcin.2020.01.230","article-title":"Thin composite-wire-strut zotarolimus-eluting stents versus ultrathin-strut sirolimus-eluting stents in BIONYX at 2 years.","volume":"13","author":"Buiten","year":"2020","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:08:41Z","timestamp":1753812521000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000949","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,4]]}}}